Melanotan I

Melanotan I is a synthetic, 13-amino-acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH), the body's natural signal for skin pigmentation. Two engineered substitutions, norleucine at position 4 and D-phenylalanine at position 7, make it more active at its target receptor and more resistant to breakdown than the natural hormone ¹. In the research literature it also goes by NDP-MSH, NDP-alpha-MSH, and CUV1647.

The same molecule is approved medicine under the name afamelanotide (SCENESSE): a 16 mg subcutaneous implant licensed by the FDA and EMA for erythropoietic protoporphyria (EPP), a rare disorder in which sunlight causes severe, painful skin reactions ⁴. In healthy skin, controlled human studies show it builds a true tan, the brown-black pigment eumelanin, without any UV exposure, and measurably blunts the skin's reddening response to ultraviolet light ⁸. It is also studied as an add-on to narrowband UVB phototherapy for repigmentation in vitiligo ⁷.

Beyond skin, the compound's anti-inflammatory signaling has drawn preclinical interest: it protects neurons in animal models of brain hemorrhage and Alzheimer's disease, though human efficacy in those settings is unproven ¹⁰.

One naming caveat matters. "Melanotan" products sold online for tanning are unlicensed, unregulated, and often not Melanotan I at all ⁵. Melanotan I is also not the same as Melanotan II, a related analog that activates a second receptor and carries appetite and sexual effects ².

Melanotan I works by standing in for alpha-MSH at the melanocortin-1 receptor (MC1R), the switch on skin pigment cells (melanocytes) that turns on tanning. MC1R is a G protein-coupled receptor, a sensor on the cell surface that relays a signal inward when the right molecule docks. Melanotan I docks with high affinity, and unlike Melanotan II it prefers MC1R over the closely related MC4R, which is why its signature effect is pigmentation rather than appetite or arousal ².

Once the receptor is switched on, the G alpha-s protein activates adenylyl cyclase, an enzyme that raises the signaling molecule cyclic AMP (cAMP) ³⁵. cAMP then activates a transcription factor called MITF, through protein kinase A and CREB, and MITF switches on tyrosinase and the other enzymes that build melanin ³. The result is a shift from red-yellow pheomelanin toward brown-black eumelanin, the pigment that absorbs ultraviolet energy and gives a true tan ³.

The same receptor system carries anti-inflammatory messages. In human immune cells called dendritic cells, NDP-MSH turns down co-stimulatory molecules that normally help activate T cells ⁴⁰. Similar activity appears in cultured cartilage cells and in animal models of brain injury, where MC1R signaling dampens oxidative stress and neuron loss ¹¹.

Human studies back the mechanism in skin. A single 16 mg implant raised measured melanin density by 2.4 to 2.9 percent within six days and reduced the skin's erythema response to UVB in nine healthy adults ⁸. An earlier randomized trial in 80 people using 0.16 mg/kg per day subcutaneously found significant melanin gains in every treated subject, largest in fair Fitzpatrick skin types I and II ⁹.

Because Melanotan I is a peptide, it is delivered by injection or implant rather than by mouth, where digestion would destroy it. The approved implant releases the drug steadily from a biodegradable PLGA polymer for about two months ¹⁷.

The evidence is strongest where the drug is approved, in erythropoietic protoporphyria (EPP), and thinner for cosmetic use in healthy skin.

Effect	Evidence strength	What the data show
EPP photoprotection	Phase 3 RCT plus registries	Longer pain-free sunlight exposure and fewer phototoxic reactions 6. One registry saw median light tolerance rise from 15 to 250 minutes and quality-of-life scores climb sharply 19. In the German registry, 91% of patients stayed on therapy 18.
Tanning in healthy skin	Small controlled studies	Melanin density up 2.4 to 2.9 percent within six days of one 16 mg implant 8. Significant tanning in all treated subjects of an n=80 trial, largest in fair skin types 9.
UV photoprotection	Small controlled studies	Reduced erythema dose-response after one implant 8; fewer sunburn cells after three times the minimal erythema dose of UV 9.
Vitiligo repigmentation	One RCT plus systematic review	Better repigmentation when implants were added to narrowband UVB phototherapy 7.
Neuroprotection	Preclinical, one feasibility trial	Less oxidative stress and neuron death after brain hemorrhage in mice 11; better cognition in Alzheimer's mouse models 13. Human stroke efficacy unproven 10.
Anti-inflammatory activity	Preclinical	Suppressed dendritic-cell activation of T cells in vitro 40; less autoantibody-driven kidney injury in a mouse model 14.

Two things the molecule does not do, from cohort data. It does not fix the underlying defect in EPP; protoporphyrin levels and liver chemistries stay unchanged ²⁰. And it does not raise vitamin D, which remains deficient in most treated patients without separate supplementation ³⁰.

Protocols in the literature sit at three very different scales.

Protocol	Route	Dose	Frequency	Evidence
EPP photoprotection (approved)	SC implant	16 mg	Every ~2 months	Phase 3 RCT and registries 6
Tanning research	SC injection	0.16 mg/kg/day	10 consecutive days per month, for 3 months	RCT, n=80 9
Vitiligo plus phototherapy	SC implant	16 mg	Implants paired with narrowband UVB sessions	RCT 7; systematic review 24

The approved EPP implant is physician-administered and releases the peptide steadily from a PLGA polymer for roughly 60 days ¹⁷. The tanning research schedule is far heavier: at 70 kg, 0.16 mg/kg per day works out to about 11 mg daily by subcutaneous injection ⁹. A separate human dose-ranging study mapped the tanning dose-response of subcutaneous Melanotan I ⁴³.

Community tanning protocols, by contrast, use much smaller subcutaneous doses. The typical pattern is a daily loading phase of 250 to 500 mcg for one to three weeks, then maintenance dosing one to two times per week, often paired with brief UV exposure. These schedules come from community practice rather than controlled trials; the timeline on this page shows the pattern phase by phase, and the safety consequences of unregulated use are documented separately ⁵.

Research vials of Melanotan I arrive as lyophilized (freeze-dried) powder that must be reconstituted before subcutaneous dosing. Bacteriostatic water is the standard diluent for multi-dose use because its benzyl alcohol preservative limits bacterial growth. Handling is simple: let the vial come to room temperature, inject the diluent slowly down the vial wall, and roll the vial gently to dissolve the powder. Do not shake it, which can damage the peptide.

Use the reconstitution calculator on this page for dose and volume arithmetic at any vial size and diluent volume.

Storage follows directly from the molecule's known chemistry. Forced-degradation studies show afamelanotide breaks down under acidic, basic, neutral, oxidative, UV-light, and heat (60 degrees C) stress, producing at least 14 degradation products through truncation, methylation, deacetylation, and oxidation ¹. In practice, unreconstituted vials are stored frozen for the long term or refrigerated in the short term, always protected from light, and reconstituted solution is kept refrigerated and used within about 30 days. Avoid repeated freeze-thaw cycles, and discard any solution that turns cloudy or develops particles.

The approved 16 mg implant needs no reconstitution. It is a solid PLGA rod supplied in a preloaded applicator and inserted by a clinician ¹⁷.

No formal drug-interaction study exists for Melanotan I, so the evidence splits into what is documented and what follows from mechanism.

Documented

• Narrowband UVB phototherapy. A true synergy: in vitiligo trials, implants added to phototherapy improved repigmentation versus phototherapy alone ⁷. The peptide also shifts the skin's erythema threshold to UVB, so phototherapy dose limits deserve reassessment once it is active ⁸.
• Vitamin D. Afamelanotide alone does not raise 25-hydroxyvitamin D, and deficiency persists in most treated patients, so cholecalciferol supplementation remains necessary alongside it ³⁰.
• Polypodium leucotomos extract. In EPP patients with incomplete implant responses, adding this fern extract improved quality of life at day 60 without adverse events ²³.
• Common co-prescribed drugs. Real-world EPP claims data show heavy co-prescribing of analgesics, NSAIDs, and antidepressants with no interaction-related safety signals ⁵⁰, and the German registry reports a favorable long-term profile ¹⁸.
• Antibody-mediated interactions. Unlikely: no new anti-drug antibodies appeared in 23 of 26 patients treated for up to six years ²⁵.

Theoretical

• Photosensitizing drugs, such as tetracyclines, fluoroquinolones, amiodarone, and retinoids: Melanotan I's photoprotection can mask the early redness that signals a phototoxic drug reaction.
• Systemic immunosuppressants. MC1R agonism is anti-inflammatory in cells, so additive immune suppression is plausible but has no clinical data ⁴⁰.
• Other melanocortin drugs, like setmelanotide and dersimelagon: combining them with Melanotan I would stack melanocortin signaling and deepen hyperpigmentation ³¹.
• CYP-metabolized drugs. Pharmacokinetic interaction is unlikely because the peptide degrades by hydrolysis and oxidation rather than liver CYP enzymes ¹.
• Melanogenesis-inhibiting botanicals, such as Tagetes erecta extracts, which suppress the cAMP-MITF-tyrosinase cascade and would oppose its tanning effect ³⁷.

Melanotan I use follows two rhythms: the steady, sometimes seasonal rhythm of the approved implant, and the on-off cycles of community tanning protocols.

In EPP practice, patients receive a 16 mg implant roughly every 60 days, and treatment often tracks the high-UV season ⁶. That schedule lifted median pain-free light tolerance from 15 minutes to 250 minutes in one observational cohort ¹⁹.

Early tanning research used discrete cycles: 0.16 mg/kg per day subcutaneously for 10 days per month, for three consecutive months ⁹. Modern community tanning protocols run far lower doses, with a typical window of 8 to 12 weeks on, followed by 4 to 8 weeks off, or dosing only around planned UV exposure periods. The underlying logic is practical. Eumelanin persists in skin for weeks after dosing stops, so once tone plateaus, extra dosing adds exposure without visible gain. Off-periods also give dermatoscopy a clean baseline for re-checking moles, because the peptide is known to darken and change existing nevi ²⁶.

Cycles can be repeated without tolerance buildup: no anti-drug antibodies emerged over up to six years of intermittent administration ²⁵. Community guidance instead points to pausing when moles change, the gums develop blue-brown discoloration, or the tan stops deepening ²⁶.

Controlled stacking research on Melanotan I does not exist, but the receptor profile sets clear expectations.

• With Melanotan II. Pharmacologically redundant: both are alpha-MSH analogs, and combining them stacks melanocortin signaling without a new benefit. Melanotan II adds MC4R-driven appetite and sexual effects and carries its own serious-event reports, so the literature frames the pairing as untested ².
• With bremelanotide (PT-141). An MT-II-derived, MC4R-targeted peptide used in sexual-health research. Combining it with Melanotan I would stack melanocortin effects across both receptors, including pigmentation and nausea, and no combination data exist.
• With growth hormone secretagogues or fat-loss peptides. Melanotan use clusters in aesthetic and fitness settings, but multi-peptide stacks have no safety evidence, and unregulated injectables carry contamination risk ⁵.
• With repair peptides such as BPC-157 and TB-500. No direct data. Melanocortins carry their own anti-inflammatory signaling, so the net immune effect of combining them is unknown ¹².

Melanotan I's regulatory story has two layers: a licensed medicine and an unlicensed lifestyle product.

As afamelanotide (SCENESSE), the molecule is FDA- and EMA-approved as a 16 mg subcutaneous implant for preventing phototoxicity in adults with erythropoietic protoporphyria (EPP), on the strength of the pivotal phase 3 trial ⁶. The approval is narrow: adult EPP only, with pediatric and adolescent use off-label ³¹. In the UK, NICE declined to fund the drug through its Highly Specialised Technologies program, the single negative decision among its 29 evaluations ⁵³. Afamelanotide is not scheduled under the US Controlled Substances Act, and WADA scheduling is not addressed in the reviewed literature.

Everything sold as "Melanotan" for tanning sits outside that framework. These products, injectable vials and nasal sprays sold through websites, gyms, and aesthetic clinics, are unlicensed and unregulated, and Dutch regulators have formally characterized population use of melanotan I and II as unlawful ⁵⁴. Social media promotion drives much of the demand, and most posts omit adverse effects ⁵. Compounding pharmacies are an active distribution channel: one reported melanoma-in-situ case involved melanotan II obtained from a regulated compounding pharmacy ²⁸.

A practical note: most illicit "melanotan" on the market is actually Melanotan II, which carries additional MC4R-driven sexual and appetite effects ⁵.

The safety profile splits sharply between the supervised implant and unregulated products.

With the approved 16 mg implant

Adverse effects are mild and transient. The German registry (n=200) shows a profile consistent with the trials and a 91 percent treatment continuation rate ¹⁸. Expected effects include generalized skin darkening, which is the intended effect but can overshoot in fair skin, plus nausea, headache, fatigue, and facial flushing that fade ¹⁹. Implant-site bruising and tenderness are transient ¹⁸. Immunogenicity is minimal: no new anti-drug antibodies appeared over up to six years of treatment ²⁵.

Distinct effects documented in case series

Blue-brown discoloration of the gums has been reported with both medical afamelanotide and self-injected melanotan ²⁷. Existing moles can darken and change under treatment, which is why dermatologic review is routine ²⁶. A case of melanoma in situ was diagnosed four weeks after starting melanotan II from a compounding pharmacy ²⁸.

Serious risks concentrate in unregulated supply

A systematic review attributes rhabdomyolysis (muscle breakdown), renal infarction, and priapism to melanotan I and II bought outside pharmaceutical channels ²⁹. Impurity and mislabeling make those products genuinely unpredictable.

Open questions

The net melanoma risk of chronic MC1R stimulation is unquantified, and mole changes are treated as the sentinel finding ²⁶. There are no human pregnancy or pediatric safety data, and vitamin D deficiency persists on treatment ³⁰.

In the literature, known hypersensitivity to the drug or implant components, a personal history of melanoma, and numerous or atypical nevi are the conditions argued against exposure ²⁶.